Stockreport

Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel

Arcellx, Inc.  (ACLX) 
PDF – Builds on Successful 2022 Collaboration on Anito-cel, a Potentially Transformative Treatment for Patients with Multiple Myeloma –– FDA Accepted Anito-cel BLA for the T [Read more]